Cargando…

New Insights into Iron Deficiency Anemia in Children: A Practical Review

Iron deficiency anemia (IDA) is the most frequent hematological disorder in children, with an incidence in industrialized countries of 20.1% between 0 and 4 years of age and 5.9% between 5 and 14 years (39 and 48.1% in developing countries). Although IDA has been recognized for a long time, there ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Moscheo, Carla, Licciardello, Maria, Samperi, Piera, La Spina, Milena, Di Cataldo, Andrea, Russo, Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029079/
https://www.ncbi.nlm.nih.gov/pubmed/35448476
http://dx.doi.org/10.3390/metabo12040289
_version_ 1784691787679399936
author Moscheo, Carla
Licciardello, Maria
Samperi, Piera
La Spina, Milena
Di Cataldo, Andrea
Russo, Giovanna
author_facet Moscheo, Carla
Licciardello, Maria
Samperi, Piera
La Spina, Milena
Di Cataldo, Andrea
Russo, Giovanna
author_sort Moscheo, Carla
collection PubMed
description Iron deficiency anemia (IDA) is the most frequent hematological disorder in children, with an incidence in industrialized countries of 20.1% between 0 and 4 years of age and 5.9% between 5 and 14 years (39 and 48.1% in developing countries). Although IDA has been recognized for a long time, there are still uncovered issues and room for improving the management of this condition. New frontiers regarding its diagnosis and therapeutic options emerge every day; recently, innovative formulations of iron have been launched, both for oral and parenteral administration, with the aim of offering treatment schedules with higher efficacy and lower toxicity. As a matter of fact, glycinate and liposomal preparations, while maintaining a satisfying efficacy profile, have significantly fewer side effects, in comparison to the traditional elemental iron salts; parenteral iron, usually considered a second-choice therapy reserved to selected cases, may evolve further, as a consequence of the production of molecules with an interesting clinical profile such as ferrocarboxymaltose, which is already available for adolescents aged >14 years. The present article reports the clinically relevant latest insights regarding IDA in children and offers a practical guide to help pediatricians, particularly to choose the most appropriate prevention and therapy strategies.
format Online
Article
Text
id pubmed-9029079
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90290792022-04-23 New Insights into Iron Deficiency Anemia in Children: A Practical Review Moscheo, Carla Licciardello, Maria Samperi, Piera La Spina, Milena Di Cataldo, Andrea Russo, Giovanna Metabolites Review Iron deficiency anemia (IDA) is the most frequent hematological disorder in children, with an incidence in industrialized countries of 20.1% between 0 and 4 years of age and 5.9% between 5 and 14 years (39 and 48.1% in developing countries). Although IDA has been recognized for a long time, there are still uncovered issues and room for improving the management of this condition. New frontiers regarding its diagnosis and therapeutic options emerge every day; recently, innovative formulations of iron have been launched, both for oral and parenteral administration, with the aim of offering treatment schedules with higher efficacy and lower toxicity. As a matter of fact, glycinate and liposomal preparations, while maintaining a satisfying efficacy profile, have significantly fewer side effects, in comparison to the traditional elemental iron salts; parenteral iron, usually considered a second-choice therapy reserved to selected cases, may evolve further, as a consequence of the production of molecules with an interesting clinical profile such as ferrocarboxymaltose, which is already available for adolescents aged >14 years. The present article reports the clinically relevant latest insights regarding IDA in children and offers a practical guide to help pediatricians, particularly to choose the most appropriate prevention and therapy strategies. MDPI 2022-03-25 /pmc/articles/PMC9029079/ /pubmed/35448476 http://dx.doi.org/10.3390/metabo12040289 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Moscheo, Carla
Licciardello, Maria
Samperi, Piera
La Spina, Milena
Di Cataldo, Andrea
Russo, Giovanna
New Insights into Iron Deficiency Anemia in Children: A Practical Review
title New Insights into Iron Deficiency Anemia in Children: A Practical Review
title_full New Insights into Iron Deficiency Anemia in Children: A Practical Review
title_fullStr New Insights into Iron Deficiency Anemia in Children: A Practical Review
title_full_unstemmed New Insights into Iron Deficiency Anemia in Children: A Practical Review
title_short New Insights into Iron Deficiency Anemia in Children: A Practical Review
title_sort new insights into iron deficiency anemia in children: a practical review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029079/
https://www.ncbi.nlm.nih.gov/pubmed/35448476
http://dx.doi.org/10.3390/metabo12040289
work_keys_str_mv AT moscheocarla newinsightsintoirondeficiencyanemiainchildrenapracticalreview
AT licciardellomaria newinsightsintoirondeficiencyanemiainchildrenapracticalreview
AT samperipiera newinsightsintoirondeficiencyanemiainchildrenapracticalreview
AT laspinamilena newinsightsintoirondeficiencyanemiainchildrenapracticalreview
AT dicataldoandrea newinsightsintoirondeficiencyanemiainchildrenapracticalreview
AT russogiovanna newinsightsintoirondeficiencyanemiainchildrenapracticalreview